Hugo Ten Cate is an expert in Hematology at Maastricht University Medical Centre (Netherlands). As of October 2026, ScienceLeadR ranks Hugo Ten Cate in the top 1% of experts worldwide for Embolism and Thrombosis. Hugo Ten Cate has authored 1,025 publications, the most recent in 2026, and is an investigator in 20 clinical trials. SLR score: 2,665 (community average: 125). How the SLR is computed.

LeadR Profile

Hugo Ten Cate Maastricht University Medical Centre Netherlands
2 665 ScienceLeadR Reputation 2665
Network Map

Hematology

Subspecialties: Cardiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Social:

Born in Amsterdam, March 9, 1958.

Married to dr. Arina ten Cate-Hoek since 1984; 2 children 3 grandchildren.

Dr. ten Cate-Hoek is also an employee at the MUMC+, where she works as a clinician-scientist in the field of venous thrombosis and post thrombotic syndrome and heads the anticoagulation clinic.


Education, positions and honors:

  1. 1987: Graduated in medicine at the University of Amsterdam.
  2. 1987: PhD thesis on “Clinical and experimental studies with a low molecular weight heparinoid”, University of Amsterdam.
  3. 1988-1990: Postdoctoral Fellow at the laboratory of prof Robert D Rosenberg and dr. Kenneth A Bauer, Beth Israel Hospital and Harvard Medical School Boston on mechanisms of inflammation associated coagulation activity.
  4. 1989-1996: Specialization in Internal medicine at Slotervaart hospital and Academic Medical Center Amsterdam.
  5. 1996-2001: Internal medicine specialist at Slotervaarthospital and Investigator at the Academic Medical Center (laboratory of Experimental Internal medicine, prof Pieter Reitsma).
  6. 1996-2002: Clinical Established investigatorship from the Dutch Heart Foundation
  7. 2002- 2025: Professor in Internal medicine, particularly in Clinical Thrombosis and Haemostasis, Maastricht University Medical Center (MUMC), Maastricht.
  8. 2012-2016: Fellow, Gutenberg Research College, Gutenberg University, Mainz.
  9. 2017-2024: Adjunct-professor, Center for Thrombosis and Haemostasis (CTH), Gutenberg University Medical Center, Mainz, Germany.
  10. 2025-2030: Professor emeritus MUMC, Maastricht


Awards:

Professor Jordan award on behalf of the Dutch Federation of Anticoagulation Clinics (2020)

Van Crevelt medal of honour (2025)

MUMC medal of honour (2025)

CARIM distinction (2025)



Management experience:

  1. 2011-2020: Chairman of the board, Dutch Federation of Anticoagulation clinics (FNT)
  2. 2008-2016: Director, Maastricht Anticoagulation Clinic
  3. 2014-2025: Director, Thrombosis Expertise Center, MUMC.
  4. 2009-2019: Chair, national committee on integrated anticoagulation care.
  5. 2012-2025: Chair, hospital committee on thrombosis management.


Professional memberships and editorial board positions:

Fellow American Heart Foundation,

Member American Society of Hematology,

Member International Society of Thrombosis and Haemostasis,

Fellow European Society of Cardiology,

Member Dutch Society for Thrombosis and Haemostasis.


Editorial boards:

Arteriosclerosis, Thrombosis and Vascular Biology; European Journal of Internal Medicine; Journal of Thrombosis and Haemostasis;

Section Editor, Thrombosis and Haemostasis;

Specialty field chief editor Thrombosis and hemostasis, Frontiers in Cardiovascular Medicine;

Section Editor, Journal of Thrombosis and Thrombolysis;

Associate Editor, European Heart Journal, Cardiovascular Pharmacology (2026- )


Member of Council ISTH: class of 2014

Co-chair SSC Animal models: 2009-2013


Congress organization:

Principal organizer of the Maastricht Consensus Conference on Thrombosis (MCCT) for 4 consecutive episodes, resulting in consensus-based publications. (doi: 10.1016/j.thromres.2015.07.033.; doi: 10.1160/TH17-07-0492; doi: 10.1055/s-0040-1708035.; doi: 10.1055/a-2052-9175).


CAS-AM postgraduate course:

I was the lead organizer of the CAS-AM course (www.cas-am.eu) focusing on complex cases of thrombosis. CAS-AM is a practice-oriented, post graduate education for medical doctors, based on problem-based learning and comprises, among others, small-group teaching, lectures, team projects and close interaction with European leaders in their field. In this highly interactive course faculty and participants mix and debate current and novel thrombosis management aspects, during 2x 4 days of physical encounter, with in-between online personal portfolio development. After 2 editions, 40 participants successfully completed this course with a certificate from Maastricht University.


Consultancies and advisory boards: past: consultant for Alveron; compensation for advisory board positions for Astra Zeneca, Galapagos, Novostia, Eli Lilly. Shareholder Coagulationprofile (small diagnostic spin off company from UM). Research support from Bayer.

Current: Shareholder Coagulationprofile (small diagnostic spin off company from UM); medical consultant for Synapse Research Institute (diagnostic R&D company, part of the Stago group).


Grant reviewer for national and international societies including DFG, Polish Science Foundation, Swiss National Science Foundation, British Heart foundation and Irish Science foundation. European Space Agency. European Research Council.

Publications: > 650 pubmed citations since 1985 (ten cate h or cate ht in pubmed)

Organizations

Career arc: 1988 - 2026

Source: PubMed

Maastricht University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1025

Citations

Citations: 36 726 1st author: 32 Last author: 133 Unique author: 29


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Antidotes for Anticoagulation Reversal.
PMID 42269153 — anticoagulants, safety, heparin, therapeutics, dabigatran, antidotes, prothrombin
N Engl J Med Top journal20260
Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A.
PMID 42254461 — treatment outcome, partial thromboplastin time, thrombin, hemophilia a, therapeutics, thromboplastin, plasma
Res Pract Thromb Haemost20260
Inhibition of inflammation reduces hypofibrinolysis in severe COVID-19: A nested case-control study within the MaastrICCht cohort.
PMID 42224841 — plasminogen activator inhibitor 1, hemorrhage, fibrinolysis, dexamethasone, case-control studies, covid-19, therapeutics, thrombosis, hemostasis
Thromb Res20260
Thrombin generation and the pharmacodynamics of parenteral anticoagulants.
PMID 42102583 — anticoagulants, thrombin, pharmacology, research, therapeutics
Pharmacol Rev20260
Andexanet alfa for the reversal of anticoagulation: Dutch practice data.
PMID 42088901 — anticoagulants, mortality, hemorrhage, incidence
Res Pract Thromb Haemost20260

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Chair: 1

By phase:

N/A 13
Phase 3 4
Phase 4 2
Phase 2 1

By status:

Completed 15
Unknown 3
Active not recruiting 1
Recruiting 1

By type:

Observational 11
Interventional 9

By Monocentric/Multicentric:

monocentric 8
multicentric2to4 1
multicentric5to9 1
multicentricup10 10

Main Topics

Cohort/Consortium Investigators 5

LeadR Networks

Main global connection map